EP1027337A4 - Integrin-rezeptor-antagonisten - Google Patents

Integrin-rezeptor-antagonisten

Info

Publication number
EP1027337A4
EP1027337A4 EP98944735A EP98944735A EP1027337A4 EP 1027337 A4 EP1027337 A4 EP 1027337A4 EP 98944735 A EP98944735 A EP 98944735A EP 98944735 A EP98944735 A EP 98944735A EP 1027337 A4 EP1027337 A4 EP 1027337A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
integrin receptor
integrin
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98944735A
Other languages
English (en)
French (fr)
Other versions
EP1027337A1 (de
Inventor
Dirk A Heerding
James M Samanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1027337A1 publication Critical patent/EP1027337A1/de
Publication of EP1027337A4 publication Critical patent/EP1027337A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP98944735A 1997-09-04 1998-09-03 Integrin-rezeptor-antagonisten Withdrawn EP1027337A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5752997P 1997-09-04 1997-09-04
US57529P 1997-09-04
US6352097P 1997-10-29 1997-10-29
US63520P 1997-10-29
PCT/US1998/018379 WO1999011626A1 (en) 1997-09-04 1998-09-03 Integrin receptor antagonists

Publications (2)

Publication Number Publication Date
EP1027337A1 EP1027337A1 (de) 2000-08-16
EP1027337A4 true EP1027337A4 (de) 2002-04-03

Family

ID=26736601

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98944735A Withdrawn EP1027337A4 (de) 1997-09-04 1998-09-03 Integrin-rezeptor-antagonisten

Country Status (4)

Country Link
EP (1) EP1027337A4 (de)
JP (1) JP2001514253A (de)
CA (1) CA2304117A1 (de)
WO (1) WO1999011626A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046215A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
WO2000048603A1 (en) * 1999-02-17 2000-08-24 Merck & Co., Inc. DIBENZO-AZEPINE DERIVATIVES AS αV INTEGRIN RECEPTOR ANTAGONISTS
JP2003506452A (ja) * 1999-08-06 2003-02-18 スミスクライン・ビーチャム・コーポレイション 発作の治療に有用なビトロネクチン受容体アンタゴニスト
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10039998A1 (de) * 2000-08-11 2002-02-21 Basf Ag Neue substituierte Diareno-azepin-Derivate als Integrin Liganden
JP2003511356A (ja) * 1999-10-06 2003-03-25 ビーエーエスエフ アクチェンゲゼルシャフト 併用療法のためのサイトカイン媒介性シグナル伝達経路のモジュレーター及びインテグリンαｖβ３受容体アンタゴニスト
DE10028575A1 (de) * 2000-06-14 2002-03-14 Basf Ag Integrinliganden
JP4660067B2 (ja) 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血管新生剤とＴＮＦαとを用いる組合せ療法
DE102004004928A1 (de) * 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
DK2101805T3 (da) 2007-01-18 2013-01-21 Merck Patent Gmbh Integrinligander til anvendelse i behandling af cancer
US20120130146A1 (en) 2009-05-25 2012-05-24 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE632563A (de) * 1963-03-26
FR1510324A (fr) * 1966-01-28 1968-01-19 Thomae Gmbh Dr K Procédés pour fabriquer de nouvelles dibenz[b, f][1, 4] oxazépine-11(10 h)-ones substituées en position 10
WO1995004057A1 (en) * 1993-07-29 1995-02-09 Genentech, Inc. TRICYCLIC INHIBITORS OF THE GPIIbIIIa RECEPTOR
EP0419861B1 (de) * 1989-08-29 1995-11-02 Boehringer Ingelheim Pharmaceuticals Inc. Verwendung von Dibenzo[b,f][1,4]oxazepin (und thiazepin)-11(10H)-one und -thione zur Herstellung eines Arzneimittels zur Prävention und Behandlung von AIDS
WO1997001540A1 (en) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
WO1998030542A1 (en) * 1997-01-08 1998-07-16 Smithkline Beecham Corporation Vitronectin receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905977A (en) * 1974-12-06 1975-09-16 Carter Wallace Octahydromorphanthridines
IT1207417B (it) * 1982-03-15 1989-05-17 Menarini Sas Azepina-6-one ad attivita'composti triciclici derivati dalla farmacologica, e procedimenti di 5,6-diidro-11h-dibenzo (b,e)fabbricazione relativi
US5512563A (en) * 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE632563A (de) * 1963-03-26
FR1510324A (fr) * 1966-01-28 1968-01-19 Thomae Gmbh Dr K Procédés pour fabriquer de nouvelles dibenz[b, f][1, 4] oxazépine-11(10 h)-ones substituées en position 10
EP0419861B1 (de) * 1989-08-29 1995-11-02 Boehringer Ingelheim Pharmaceuticals Inc. Verwendung von Dibenzo[b,f][1,4]oxazepin (und thiazepin)-11(10H)-one und -thione zur Herstellung eines Arzneimittels zur Prävention und Behandlung von AIDS
WO1995004057A1 (en) * 1993-07-29 1995-02-09 Genentech, Inc. TRICYCLIC INHIBITORS OF THE GPIIbIIIa RECEPTOR
WO1997001540A1 (en) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
WO1998030542A1 (en) * 1997-01-08 1998-07-16 Smithkline Beecham Corporation Vitronectin receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAGARAJAN, K. ET AL: "Condensed heterotricycles. Potential metabolites of dibenz[b,f][1,4]oxazepine antidepressant, Sintamil", INDIAN J. CHEM. (1974), 12(3), 270-4, XP001055872 *
See also references of WO9911626A1 *

Also Published As

Publication number Publication date
WO1999011626A1 (en) 1999-03-11
CA2304117A1 (en) 1999-03-11
JP2001514253A (ja) 2001-09-11
EP1027337A1 (de) 2000-08-16

Similar Documents

Publication Publication Date Title
EP1047425A4 (de) Integrinrezeptor antagonisten
EP1007051A4 (de) Integrin rezeptor antagonisten
EP1100506A4 (de) Integrin rezeptor antagonisten
EP1105389A4 (de) Integrinreceptorantagonisten
EP1007026A4 (de) Integrin-antagonisten
EP0934305A4 (de) Integrinantagonisten
EP0880511A4 (de) Integrin-rezeptor-antagonisten
ZA9896B (en) Vitronectin receptor antagonists
EP1229910A4 (de) Integrinrezeptorantagonisten
EP1194151A4 (de) Antagonisten der integrin rezeptoren
IL135797A0 (en) Thrombin receptor antagonists
IL135028A0 (en) Vitronectin receptor antagonists
PL342881A1 (en) Vitronectin receptor antagonists
EP1027337A4 (de) Integrin-rezeptor-antagonisten
IL148043A0 (en) Novel integrin receptor antagonists
IL146146A0 (en) Integrin receptor antagonists
IL141163A0 (en) Vitronectin receptor antagonists
ZA9811500B (en) Integrin receptor antagonists
ZA986930B (en) Integrin receptor antagonists
GB9603373D0 (en) Integrin receptor antagonists
IL119820A0 (en) Integrin receptor antagonists
ZA988562B (en) Vitronectin receptor antagonists
ZA9610690B (en) Integrin receptor antagonists.
GB9811283D0 (en) Vironectin receptor antagonists
ZA9610873B (en) Integrin receptor antagonists.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000313

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20020220

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 223/20 A, 7A 61K 31/55 B, 7C 07D 413/12 B

17Q First examination report despatched

Effective date: 20021025

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040608